Anti-thymocyte globulin

Jump to navigation Jump to search

WikiDoc Resources for Anti-thymocyte globulin

Articles

Most recent articles on Anti-thymocyte globulin

Most cited articles on Anti-thymocyte globulin

Review articles on Anti-thymocyte globulin

Articles on Anti-thymocyte globulin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Anti-thymocyte globulin

Images of Anti-thymocyte globulin

Photos of Anti-thymocyte globulin

Podcasts & MP3s on Anti-thymocyte globulin

Videos on Anti-thymocyte globulin

Evidence Based Medicine

Cochrane Collaboration on Anti-thymocyte globulin

Bandolier on Anti-thymocyte globulin

TRIP on Anti-thymocyte globulin

Clinical Trials

Ongoing Trials on Anti-thymocyte globulin at Clinical Trials.gov

Trial results on Anti-thymocyte globulin

Clinical Trials on Anti-thymocyte globulin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Anti-thymocyte globulin

NICE Guidance on Anti-thymocyte globulin

NHS PRODIGY Guidance

FDA on Anti-thymocyte globulin

CDC on Anti-thymocyte globulin

Books

Books on Anti-thymocyte globulin

News

Anti-thymocyte globulin in the news

Be alerted to news on Anti-thymocyte globulin

News trends on Anti-thymocyte globulin

Commentary

Blogs on Anti-thymocyte globulin

Definitions

Definitions of Anti-thymocyte globulin

Patient Resources / Community

Patient resources on Anti-thymocyte globulin

Discussion groups on Anti-thymocyte globulin

Patient Handouts on Anti-thymocyte globulin

Directions to Hospitals Treating Anti-thymocyte globulin

Risk calculators and risk factors for Anti-thymocyte globulin

Healthcare Provider Resources

Symptoms of Anti-thymocyte globulin

Causes & Risk Factors for Anti-thymocyte globulin

Diagnostic studies for Anti-thymocyte globulin

Treatment of Anti-thymocyte globulin

Continuing Medical Education (CME)

CME Programs on Anti-thymocyte globulin

International

Anti-thymocyte globulin en Espanol

Anti-thymocyte globulin en Francais

Business

Anti-thymocyte globulin in the Marketplace

Patents on Anti-thymocyte globulin

Experimental / Informatics

List of terms related to Anti-thymocyte globulin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: ATG

Overview

Anti-thymocyte globulin (ATG) is an infusion of rabbit-derived antibodies against human T cells which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia.

In the United States it is frequently given at the time of the transplant to prevent rejection, although many European centres prefer to reserve its use for the treatment of steroid-resistant acute rejection, as European centres generally serve more homogeneous populations and rejection tends to be less of a problem.

ATG is associated with cytokine release syndrome when it is used, and in the longer term may increase the risk of post-transplant lymphoproliferative disorder as well as (theoretically) impairing the development of immunological tolerance. Temporary depletion of the T cell population at the time of the transplant also risks delayed acute rejection, which may be missed and cause severe damage to the graft.

Anti-IL-2Rα receptor antibodies such as basiliximab and daclizumab are increasingly being used in place of ATG as an induction therapy, as they do not cause cytokine release syndrome and (theoretically) improving the development of tolerance.

Frequently associated with high grade fevers over 39C, chills, and possibly rigors during administration. These can often be reduced by slowing the infusion rate.

References